The Conversation (0)
XkeYrsK5P6m0XQfEcX-k-vjqfClsCTux3ab-3kE0yWYzS1_OQXi7PYNox-BVBPbTGoiolxIY28PA1drTKXjqzsZ3GEvt6LnNyHJNiaV99d9" target="_blank" rel="nofollow">XkeYrsK5P6m0XQfEcX-k-seiY0toxvZe9Wd6PScvUERsd6zXdDalfxBEpU8D13cfnHY4Oa_rrTb2UZBLN7zKbuZO-F3zOedpATgAt5qditX" target="_blank" rel="nofollow">Cullinan Therapeutics, Inc. (Nasdaq: CGEM; "Cullinan"), a clinical-stage biopharmaceutical company accelerating potential first- or best-in-class, high-impact therapies in autoimmune diseases and cancer, today announced that Nadim Ahmed, Chief Executive Officer, and Jeffrey Jones, M.D., M.B.A., Chief Medical Officer, will participate in a fireside chat at the Citi 2026 Virtual Oncology Leadership Summit on Thursday, February 19, 2026, at 10:00 a.m. ET.
A webcast of the fireside chat will be available under the Events and Presentations section of the Company's investor relations website at https://investors.cullinantherapeutics.com/events.
About Cullinan Therapeutics
Cullinan Therapeutics, Inc. (Nasdaq: CGEM) is a biopharmaceutical company developing potential first- or best-in-class, high-impact therapies for autoimmune diseases and cancer. Cullinan pursues promising therapeutic targets while leveraging core expertise in T cell engagers, which are established in oncology and are now advancing into autoimmune diseases. With a clinical-stage pipeline built on a rigorous scientific approach and purposeful innovation, Cullinan is advancing its mission to deliver new standards of care for patients. Learn more about Cullinan at https://cullinantherapeutics.com/, and follow Cullinan on LinkedIn and X.
Contacts:
Investors
Nick Smith
+1 401.241.3516
nsmith@cullinantx.com
Media
Rose Weldon
+1 215.801.7644
rweldon@cullinantx.com
